Orexin Receptor Type 1 – Drugs In Development, 2021

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) – Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 2, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Respiratory and Gastrointestinal which include indications Binge Eating Disorder, Insomnia, Nicotine Addiction, Obstructive Sleep Apnea, Opium (Opioid) Addiction, Addiction, Alcohol Addiction, Chronic Obstructive Pulmonary Disease (COPD), Delirium, Dementia, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Mild Cognitive Impairment, Narcolepsy, Panic Disorders, Parkinson's Disease, Reflux Esophagitis (Gastroesophageal Reflux Disease), Sleep Disorders and Smoking Cessation.

The latest report Orexin Receptor Type 1 – Drugs In Development, 2021, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

– The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Chronos Therapeutics Ltd

Eisai Co Ltd

Eolas Therapeutics Inc

Idorsia Pharmaceutical Ltd

Indivior Plc

Inexia Ltd

Johnson & Johnson

Merck & Co Inc

OXonium Therapeutics

Taisho Pharmaceutical Holdings Co Ltd

Yangtze River Pharmaceutical Group

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development

Chronos Therapeutics Ltd

Eisai Co Ltd

Eolas Therapeutics Inc

Idorsia Pharmaceutical Ltd

Indivior Plc

Inexia Ltd

Johnson & Johnson

Merck & Co Inc

OXonium Therapeutics

Taisho Pharmaceutical Holdings Co Ltd

Yangtze River Pharmaceutical Group

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles

ACT-539313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-010018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daridorexant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EORA-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INDV-2000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3215 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lemborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-142 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YZJ-1139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones

Featured News & Press Releases

Jun 30, 2021: Eisai launches in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong

Jun 09, 2021: Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021

Jun 09, 2021: Eisai to present latest data of Lemborexant at 35th Annual Sleep Meeting

Mar 10, 2021: FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia

Mar 03, 2021: Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia

Mar 02, 2021: New Drug Approval for in-house developed anti-insomnia drug Dayvigo (Lemborexant) in Hong Kong

Feb 04, 2021: Health Canada authorizes DAYVIGO (lemborexant)

Nov 02, 2020: Eisai to present on lemborexant at Digital CTAD 2020

Oct 28, 2020: Eisai to present on lemborexant at 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference

Aug 28, 2020: Eisai presents new analyses from phase 3 studies of DAYVIGO (lemborexant) CIV for the treatment of insomnia in adult patients at Virtual SLEEP 2020

Aug 28, 2020: Daridorexant Phase 3 results in insomnia presented at SLEEP 2020

Aug 25, 2020: Eisai to present latest data of lemborexant at 34th Annual Sleep Meeting (SLEEP 2020)

Aug 13, 2020: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020

Aug 06, 2020: Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia - preparation for a local registration program advancing

Jul 22, 2020: Eisai to present latest data on Lemborexant at the Alzheimer’s Association International Conference (AAIC) 2020

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Chronos Therapeutics Ltd, 2021

Pipeline by Eisai Co Ltd, 2021

Pipeline by Eolas Therapeutics Inc, 2021

Pipeline by Idorsia Pharmaceutical Ltd, 2021

Pipeline by Indivior Plc, 2021

Pipeline by Inexia Ltd, 2021

Pipeline by Johnson & Johnson, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by OXonium Therapeutics, 2021

Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021

Pipeline by Yangtze River Pharmaceutical Group, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports